Pharmacokinetic evaluation of pemetrexed

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 7, 2011, Pages 919-928

  Sørensen, Jens Benn ^a  

^a Rigshospitalet   (Denmark)

Author keywords

antimetabolite; CNS distribution; NSAID; pemetrexed; pharmacokinetic; renal impairment; third space fluid

Indexed keywords

ACETYLSALICYLIC ACID; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FOLIC ACID; GEMCITABINE; IBUPROFEN; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PENTETATE TECHNETIUM TC 99M;

BODY FLUID; CEREBROSPINAL FLUID; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; LIVER METABOLISM; PLASMA CLEARANCE; PUBLICATION; REVIEW; STEADY STATE; THIRD SPACE FLUID;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; DRUG EVALUATION; DRUG INTERACTIONS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; KIDNEY NEOPLASMS; LIVER; MESOTHELIOMA; PLATINUM COMPOUNDS; TISSUE DISTRIBUTION; VITAMINS;

EID: 79959269969     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.587411     Document Type: Review

References (71)

1. Bertino JR. Karnofsky memorial lecture: ode to methotrexate. J Clin Oncol 1999;11:5-14
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8 (Pubitemid 37328853)
3. Saif MW, Chu E. Antimetabolites. In: DeVita VT Jr, Rosenbegr AE, Lawrence TS, editors, Cancer: principles & practice of oncology. 8th edition. Lippincott, Williams & Wilkins, Philadelphia; 2008. p. 427-36
4. Sørensen JB. Current concepts in chemotherapy for Malignat Pleural Mesothelioma. Clin Respir J 2008;2:74-9
5. Fuld AD, dragney KH, Rigas JR. Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother 2010;11:1387-402
6. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23
7. Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamaation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999;26:42-7 (Pubitemid 29218027)
8. Schultz RM, Parel VF, Worzalla JF, Shich C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19:437-43 (Pubitemid 29168274)
9. Grindey GB, Shih C, Barnett CJ. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res Annu Meet 1992;33:411
10. Racannelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009;69:5467-74
11. Fossela FV, Gatzemeier U. Phase I trials of Pemetrexed. Semin Oncol 2002;29(5 Suppl):8-16 (Pubitemid 34564408)
12. Li KM, Rivory LP, Clarke SJ. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimization of Pemetrexed schedules. Br J Cancer 2007;97:1071-6 (Pubitemid 47587013)
13. Vogelzang N, Rusthoven J, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;23:2636-44 (Pubitemid 46606305)
14. Bunn P, Paoletti P, Niyikiza C, et al. Vitamin B12 and folate reduce toxicity of alimta (pemetrexed disodium, LY231514, MTA) a novel antifolate/antimetabolite [abstract 300]. Proc Am Soc Clin Oncol 2001;20:76a
15. Adjei AA. Current data with Pemetrexed (Alimta®) in non-small cell lung cancer. Clin Lung Cancer 2003;4(2 Suppl):s64-7
16. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002;29(5 Suppl):3-7 (Pubitemid 34564407)
17. Rinaldi DA, Burris, HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-50
18. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-80 (Pubitemid 29455582)
19. McDonald AC, Vasey PA, Adams L. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998;4:605-10 (Pubitemid 28193558)
20. Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006;57:401-11 (Pubitemid 43087583)
21. Rinaldi DA. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 1999;26(2 Suppl 6):82-8 (Pubitemid 29218033)
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
23. Eli Lilly and Co. Package insert: Alimta, Pemetrexed for injection. 2004
24. Egorin MJ. Horsehsoes, hand grenades, and body-surface area-based dosing: aming for a target. J Clin Oncol 2003;21:182-3 (Pubitemid 46606144)
25. Felici A, Verweij J, Spaareboom A. Dosing strategies for anticancer drugs: the good, the bad, and the body-surface area. Eur J Cancer 2002;38:1677-84
26. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19:171-7 (Pubitemid 32423722)
27. Ratain MJ. Body-surface area as a basis for dosing of antican cer agents: science, myth, or habit? J Clin Oncol 1998;16:2297-8 (Pubitemid 28309019)
28. Reilly JJ, Workman P. Normalisation of anticancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 1993;32:411-18 (Pubitemid 23234656)
29. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 1993;7:1344-53 (Pubitemid 23336162)
30. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med 1999;159:1289-98 (Pubitemid 29293591)
31. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52
32. Celio L, Bajetta E, Toffolatti L, et al. Phase II trial of pemetrexed disodium administered every 21 days in patients with gastric cancer: efficacy and toxicity with and without folic acid [abstract 284P]. J Steroid Biochem Mol Biol 2000;11:65
33. John W, Picus J, Blanke C, et al. Activity of multitargeted antifolate (pemetrexed disodium, LY-231514) in patient with advanced colorectal carcinoma: results from a phase II study. Cancer 2000;88:1807-13 (Pubitemid 30212989)
34. Adjei AA. Pemetrexed (Alimta®): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 2003;3:145-56 (Pubitemid 36503392)
35. Mita AC, Sweeney CJ, Baker SD, et al. Phase I and Pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-6
36. Wan SH, Huffman DH, Azarnoff DL, et al. Effect of route of administration and effusions on methotrexate pharmacokinetic. Cancer Res 1974;34:3487-91
37. Chabner BA, Stoller RG, Hande K, et al. Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion. Drug Metab Rev 1978;8:107-17 (Pubitemid 9051925)
38. Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978;23:68-72 (Pubitemid 8290412)
39. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002;50:373-82 (Pubitemid 35440526)
40. Chabner BA, Young RC. Treshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and timorous target tissues. J Clin Invest 1973;52:1804-11
41. Dickgreber NJ, Sørensen JB, Paz-Ares LG, et al. Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 2010;16:2872-80
42. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advamced or metastatic cancer. Clin Cancer Res 2007;13:2675-83 (Pubitemid 46788035)
43. Sørensen JB, Sundstrøm S, Perell K, Thielsen A-K. Pemetrexed as second line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007;2:147-52 (Pubitemid 47181344)
44. Monjanel-Mouterde S, Frenay C, Catalin J, et al. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusion. Oncol Rep 2000;7:171-5
45. Lerza R, Vannozzi MO, Tolino G, et al. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol 1997;8:385-91 (Pubitemid 27230981)
46. Greillier L, Monjanel-Mouterde S, Fraticelli A, et al. Intrapleural administration of Pemetrexed: a pharmacokinetic study in an animal model. J Thorac Oncol 2009;4:404-8
47. Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 2002;62:3144-50 (Pubitemid 34602407)
48. Hooilberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5 (Pubitemid 29269093)
49. Dai H, Chen Y, Elmquist WF. Distribution of the novel antifolate pemetrexed to the brain. JPET 2005;315:222-9 (Pubitemid 41380515)
50. McCully CL, Balis FM, Bacher J, et al. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 1990;40:520-5 (Pubitemid 20372873)
51. Stapleton SL, Reid JM, Thompson PA, et al. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intraveneous administration in non-human primates. Cancer Chemother Pharmacol 2007;59:461-6 (Pubitemid 46122324)
52. Frenia ML, Long KS. Methotrexate and nonsteroidal anti-inflammatory drug interactions. Ann Pharmacother 1992;26:234-7
53. Liegler DG, Henderson ES, Hahn MA, et al. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969;10:849-57
54. Sweeney CJ, Takimoto CH, Latz JE, et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin Cancer Res 2006;12:536-42 (Pubitemid 43166146)
55. Misset JL, Gamelin E, Campone M, et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol 2004;15:1123-9 (Pubitemid 39089790)
56. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000;18:1748-57 (Pubitemid 30220554)
57. Dy GK, Suri A, Sloan JA, et al. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol 2005;55:522-30 (Pubitemid 40674627)
58. Li KM, Rivory LP, Clarke SJ. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II sudy of doublet chemotherapy with vinorelbine: implications for further optimization of pemetrexed schedules. Br J Cancer 2007;97:1071-6 (Pubitemid 47587013)
59. Rowinsky EK, beeram M, hammond LA, et al. A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Clin Cancer Res 2007;13:532-9
60. Hughes AN, Lind M, Azzabi A, et al. A phase I dose escalation study of doxorubicin in combination with pemetrexed [abstract 438]. Breast Cancer Res Treat 2001;69:286 (Pubitemid 33789153)
61. Graefe T, Bolling C, Lubbing C, et al. Pemetrexed in combination with paclitaxel: a phase I clinical and pharmacokinetic trial in patients with solid tumors. Proc Am Soc Clin Oncol 2006;42:abstract 2051
62. Paridaens R, Dirix L, Dumez H, et al. Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. Clin Breast Cancer 2007;7:861-6
63. Dittrich C, Petrulzelka L, Vodvarka P, et al. A phase I study of pemetrexed (ALIMTA) and cyclophosphaamide in patients with locally advanced or metastatic breast cancer. Clin Cancer Res 2006;12:7071-8 (Pubitemid 44974506)
64. Hughes Á, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533-44
65. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999;17:3009-16 (Pubitemid 29470627)
66. Dickgreber N, Fink TH, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res 2009;15:382-9
67. Cullen MH, Zatloukal P, Sorenson S, et al. A randomized phase III trial comparing standard andhigh-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer. Ann Oncol 2008;19:939-45 (Pubitemid 351627311)
68. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-12
69. Latz J, Claret L, Symanowski J, et al. Evaluation of pemetrexed (PEM) dosing paradigms using exposure-response relationships (ERRs). J Clin Oncol 2007;25:2530
70. Ranson M, Reck M, Anthoney A, et al. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Ann Oncol 2010;21:2233-9
71. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of Pemetrexed/carboplatin/bevacizumab followed by maintenance Pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-6